As expected, silence of SNHG12 or anti-cancer drugs (cisplatin, paclitaxel or gefitinib) treatment promoted caspase3 and caspase9 activities in A549/DDP, A549/PTX and PC9/AB2 cells, however, combination of si-SNHG12 and drug treatment resulted in a significant increase in caspase3 and caspase9 activities in A549/DDP, A549/PTX and PC9/AB2 cells than any single treatment group (Figure 3J-3L). This evidence concerns the gene SNHG12 and cancer.